Funding for this research was provided by:
Received: 16 May 2021
Accepted: 24 December 2021
First Online: 2 February 2022
: The study was approved by the Ethics committee at Lund University (reference number 445-2007). In accordance with national legislation and institutional requirements, the committee waived the need for informed consent other than the option to opt out. All methods were carried out in accordance with relevant guidelines and regulations.
: Not applicable.
: W.M. Gallagher is a co-founder, shareholder and Chief Scientific Officer in OncoMark Limited, and reports receiving commercial research grants from and is an unpaid Scientific Advisory Board member with Carrick Therapeutics. The other authors declare no competing interest.